The Study Population Excludes Older Adults: What That Limits

By ClinicalStudyConnect.com Research Desk

If a study you are reading excluded people over a certain age, or excluded people with the health conditions you actually have, the results may not tell you much about what will happen to you. That is the short answer. The longer answer is that “excludes older adults” can mean several different things — a hard age cutoff, a ban on common comorbidities that concentrate in older age groups, or eligibility rules that quietly filter out frailty and polypharmacy without ever mentioning age at all — and each version limits the evidence differently. This guide explains how to spot the exclusion, what it does and does not tell you, and gives you a short worksheet for checking population fit on any study you read next.

What “Eligibility Criteria” Actually Controls

Every clinical trial record lists eligibility criteria, split into two parts: inclusion criteria, which a participant must meet to join, and exclusion criteria, which keep certain people out. The National Institutes of Health’s Center for Advancing Translational Sciences defines them as “the requirements that must be met for a person to be included in the study,” designed so that participants share common characteristics — age, disease stage, overall health, prior treatment — which increases the odds that any effect seen in the results comes from the treatment and not from differences between participants (NCATS Toolkit, “Eligibility Criteria”).

That design goal is legitimate. A tightly defined population makes a trial easier to run and its results easier to interpret for the people who matched the criteria. The tradeoff is generalizability: the more a trial narrows its population, the less its results say about anyone who falls outside that window — including, very often, older adults.

How Older Adults Get Filtered Out

Age exclusion is rarely just a number in the eligibility list. Research on trial enrollment patterns points to several overlapping mechanisms:

Direct age caps. Some protocols set an upper age limit outright, independent of a participant’s actual health status.
Comorbidity exclusions. Trials frequently exclude people with additional diagnosed conditions, and comorbidities become more common with age — so a “no comorbidities” rule filters out older participants indirectly even without naming age.
Polypharmacy exclusions. Rules that exclude anyone taking multiple concurrent medications disproportionately remove older adults, who are more likely to be on several prescriptions at once.
Functional and cognitive requirements. Criteria tied to functional independence or cognitive status can exclude frail participants, and researchers have noted that obtaining informed consent from people with cognitive impairment raises ethical and logistical questions that some trials sidestep by excluding them entirely.

The result is a research gap that specifically affects frail older adults, who are documented as major users of prescription medications yet are often the group least represented in the trials that test those medications (USC Ostrow School of Dentistry, “The Gray Area of Clinical Trials: Why Older Adults Are Missing Out?”).

What the Numbers Show

A systematic review of 300 randomized controlled trials published in 2012 examined how well trials designed for older adults actually report on the characteristics that determine whether results apply to a given older patient. Even among trials specifically designed for older populations, only 34% reported on physical functioning, mental functioning, somatic status, social environment, or frailty. Frailty status specifically was reported in just 1% of trials. Reporting improved only when trials restricted enrollment to much older participants: trials with a mean participant age of 80 or above reported these characteristics 85% of the time, but such trials made up only 1% of all trials reviewed. The review’s authors concluded that this underreporting leaves it “unclear… to which older patients the results can be applied” (PLOS ONE, “External validity of randomized controlled trials in older adults, a systematic review”).

Field-specific reporting points in the same direction. Secondary coverage of oncology trial enrollment describes cancer patients age 65 and older as roughly two-thirds of the diagnosed population but historically closer to a quarter of clinical trial enrollment, citing the MOSAIC colorectal cancer trials — median participant age 60 against a median diagnosis age of 70 for the disease studied — as one example (USC Ostrow, 2024). Those specific enrollment figures come from secondary reporting rather than the original trial publications, so treat them as a reported pattern rather than a precise number to cite on their own.

Why This Matters Even When the Trial Worked

A trial that excluded older adults, or people with your specific comorbidities, can still be a well-run trial. The problem is not the trial’s internal validity — it is what the result can be extended to say. Specifically, a population gap limits what you can conclude about:

How the treatment performs in your body. Age-related changes in kidney function, liver metabolism, body composition, and drug clearance can change how a treatment behaves, and a trial that excluded older participants has no direct data on that.
Interactions with other conditions or medications. If people with multiple diagnoses or multiple prescriptions were excluded, the trial cannot tell you what happens when the studied treatment is layered onto a real, multi-condition medication list.
Dosing. A dose established as safe and effective in a younger, healthier population is not automatically the right dose for someone with reduced organ function or additional conditions.
Whether benefit outweighs risk for your subgroup. Researchers who study this gap distinguish between “fit,” “vulnerable,” and “frail” older adults as separate categories with potentially different risk-benefit profiles — and trials that exclude older participants outright provide no data on any of the three.

None of this means the treatment does not work for older adults or people with comorbidities. It means the trial did not test that question, and the honest answer to “does this apply to me” is that it has not been established either way.

Regulators Have Flagged the Same Gap

This is not only an academic observation. The U.S. Food and Drug Administration has issued formal guidance on the problem, at least in oncology. Its March 2022 guidance, Inclusion of Older Adults in Cancer Clinical Trials, defines older adults as those 65 and older, places particular emphasis on adults over 75, and states that inadequate enrollment of older patients limits the agency’s and clinicians’ ability to evaluate a cancer drug’s benefit-risk profile in the population most likely to use it after approval. The guidance recommends that sponsors enroll a representative range of ages, avoid unnecessary age-based eligibility restrictions, and report age-specific information in drug labeling where the data supports it (FDA, “Inclusion of Older Adults in Cancer Clinical Trials”).

That guidance is specific to cancer drug trials. It is a useful signal that regulators recognize the problem, but it does not mean the same standard is enforced across every disease area — which is exactly why checking a given study’s actual eligibility criteria, rather than assuming the field has fixed this, remains the reader’s job.

Where to Check This on a Study You’re Reading

Two places in a published trial report or registry entry tell you what you need:

The eligibility criteria section. Every registered trial record on ClinicalTrials.gov lists inclusion and exclusion criteria in full. This is where age caps, comorbidity exclusions, and functional requirements are stated explicitly.
The participant flow diagram. Trials reported under the CONSORT guidelines — the standard framework for reporting randomized trial results — include a flow diagram showing how many people were assessed, excluded, randomized, and analyzed. Trial protocols following the companion SPIRIT guidelines set out eligibility criteria before the trial begins. Neither guideline can force a sponsor to include older or sicker participants, but both require the exclusions that did happen to be disclosed rather than buried (CONSORT-SPIRIT).

If a summary, press release, or news article about a study doesn’t mention the age range or health status of participants, that omission is itself informative — go to the original registry entry or published methods section rather than taking the summary’s framing at face value.

Population-Fit Worksheet

Use this on any study before deciding how much its results apply to you or someone you’re helping. It is a reading checklist, not a scoring system — the goal is to see where the gaps are, not to produce a pass/fail verdict.

Age range enrolled. What were the stated minimum and maximum ages? Was there an upper cutoff, and if so, is it above or below the age of the person you’re asking about?
Median or mean participant age. Separate from the allowed range, what age did the typical participant actually turn out to be? A trial can technically allow older participants and still enroll very few of them.
Comorbidity exclusions. Does the exclusion list name specific conditions the person you’re asking about has? A single relevant exclusion can be enough to make the results not apply.
Medication-count exclusions. Did the trial exclude people on multiple concurrent medications? If so, and the person you’re asking about takes several prescriptions regularly, the trial’s safety data may not reflect that situation.
Functional or cognitive requirements. Did participants need to meet an independence, mobility, or cognitive-status threshold to enroll?
Subgroup reporting. Did the published results break outcomes down by age group, or only report one overall result for the full study population? A study that enrolled some older participants but never separated their outcomes still leaves the age-specific question unanswered.
Follow-up duration. Is the follow-up period long enough to be relevant to the time horizon that matters for an older adult’s decision, or was it designed around a younger population’s expected course?

If a study fails several of these checks for your situation, that is not a reason to dismiss it — it is a reason to treat its results as evidence about the population it actually studied, and to look for corroborating research, or a clinician’s judgment, before assuming the findings transfer.

What Remains Unresolved

A few open questions are worth naming plainly rather than glossing over:

Enrollment expectations and formal FDA guidance addressing this gap are strongest in oncology; the same formal expectations have not been established uniformly across every therapeutic area, so the degree of underrepresentation varies by field.
Published statistics on “how underrepresented” older adults are vary by review, by year, and by how each review defines the older-adult threshold (65+, 75+, or another cutoff) — there is no single agreed-upon figure that applies across all of medicine.
Even when a trial does enroll older participants, published results do not always separate outcomes by age subgroup or report the functional and frailty characteristics needed to judge fit, which limits what conclusions can be drawn even from trials that were more inclusive at enrollment.

The Next Practical Step

Before treating any study’s results as a personal answer, run its eligibility criteria and participant age data through the worksheet above. If the study population doesn’t reflect your age, comorbidities, or medication list, that gap is worth raising directly with a clinician who knows your full health picture — they can weigh whether the available evidence still applies, whether dose or monitoring adjustments are reasonable, or whether better-matched evidence exists elsewhere.

This article is for general research literacy and does not provide medical advice, diagnosis, or treatment recommendations, and it does not evaluate or endorse any product. Talk with a qualified healthcare provider about whether a specific study’s findings are appropriate to apply to your own health situation, particularly if you are older or manage multiple health conditions.